Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection
This study indicates that universal infant immunization with nirsevimab has the potential to be cost effective and significantly reduces the burden of RSV among Dutch infants. These findings underscore the importance of implementing effective protective measures against RSV-LRTD, reducing the pressure on the healthcare system during the RSV season.
Authors
- Florian Zeevat (ORCID: https://orcid.org/0000-0001-6427-4172)
- Cornelis Boersma (ORCID: https://orcid.org/0000-0002-1190-2638)
- Maarten Jacobus Postma (ORCID: https://orcid.org/0000-0002-6306-3653)
- Simon van der Pol (ORCID: https://orcid.org/0000-0003-1784-1001)
- Alexia Kieffer (ORCID: https://orcid.org/0009-0004-5735-195X)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Sanofi (France) (FR)
- Pension Fund for Care and Well-Being (NL)
- Open University of the Netherlands (NL)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1007/s40273-025-01469-0
- Citations
- 4
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Sanofi